Sign up USA
Proactive Investors - Run By Investors For Investors

Cancer doctors offer key takeaways from American Society of Clinical Oncology conference

Merck's lung cancer-fighting drug Keytruda has just been approved for the treatment of cervical cancer
Cancer in a headline
Attendees at the ASCO conference were also bullish on the combination of Opdivo with Yervoy

An important takeaway to come out of the American Society of Clinical Oncology conference early this month is that Merck’s lung cancer-fighting drug Keytruda is quite similar in its efficacy and safety to Bristol-Myers Squibb Co’s (NYSE:BY) Opdivo.

This insight is the view of two attendees at the ASCO conference,  Dr. Jack Goldberg, chief of hematology and medical oncology at Penn Presbyterian Medical Center and Dr. Igor Genkin who practices in the Bronx with an emphasis on biomarker development.

Both offered opinions on the conference to Oppenheimer analysts.

“These doctors view Keytruda and Opdivo as very similar in terms of efficacy and safety with differences arising from their respective study designs in lung cancer,” wrote Oppenheimer analysts.

The stage three data for AstraZeneca PLC’s (NYSE:AZN) rival drug Imfimzi is also seen by both doctors as compelling and the data on the drug provided at ASCO will likely accelerate utilization, the doctors predict.

Another drug therapy both Goldberg and Genkin are positive on is the combination of Opdivo with Yervoy in lung cancer patients.

Both believe that precision oncology is likely to become “very impactful to their practices” as new emphasis is placed on targeting mutations rather than the cells of origin. They are also bullish on the use of biomarkers in their practices and look forward to future clinical studies.

In other news today, Merck (NYSE:MRK) confirmed that the US Food and Drug Administration has also approved Keytruda, a popular weapon against lung cancer, for the treatment of patients with recurrent or metastatic cervical cancer.

View full BMY profile View Profile

Bristol Myers Squibb Timeline

Related Articles

myLotus kit
August 06 2018
The expansion drive is targeting an estimated 2.3mln women per year in the areas of Hebei, Shanghai, Beijing, Shangdong, Henan and Liaoning
1511901712_biotech_517925923.jpg
November 29 2017
The company has developed a "unique and superior pressure" cycling technology (PCT), says Zacks.
1528305384_Untitled-design-(3).jpg
June 06 2018
Ventripoint received key FDA approval to sell the device with the four-chamber heart analysis last month

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume this write-up may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Copyright © Proactiveinvestors.com, 2018. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use